Elevated Serum Levels of Interferon-regulated Chemokines Are Biomarkers for Active Human Systemic Lupus Erythematosus

Overview

Journal PLoS Med

Specialty General Medicine

Date 2006 Dec 21

PMID 17177599

Citations 147

Authors

Jason W Bauer

Emily C Baechler

Michelle Petri

Franak M Batliwalla

Dianna Crawford

Ward A Ortmann

Karl J Espe

Wentian Li

Dhavalkumar D Patel

Peter K Gregersen

Timothy W Behrens

Affiliations

Soon will be listed here.

Abstract

Background: Systemic lupus erythematosus (SLE) is a serious systemic autoimmune disorder that affects multiple organ systems and is characterized by unpredictable flares of disease. Recent evidence indicates a role for type I interferon (IFN) in SLE pathogenesis; however, the downstream effects of IFN pathway activation are not well understood. Here we test the hypothesis that type I IFN-regulated proteins are present in the serum of SLE patients and correlate with disease activity.

Methods And Findings: We performed a comprehensive survey of the serologic proteome in human SLE and identified dysregulated levels of 30 cytokines, chemokines, growth factors, and soluble receptors. Particularly striking was the highly coordinated up-regulation of 12 inflammatory and/or homeostatic chemokines, molecules that direct the movement of leukocytes in the body. Most of the identified chemokines were inducible by type I IFN, and their levels correlated strongly with clinical and laboratory measures of disease activity.

Conclusions: These data suggest that severely disrupted chemokine gradients may contribute to the systemic autoimmunity observed in human SLE. Furthermore, the levels of serum chemokines may serve as convenient biomarkers for disease activity in lupus.

Citing Articles

Rethinking of phosphodiesterase 5 inhibition: the old, the new and the perspective in human health.

Paronetto M, Crescioli C Front Endocrinol (Lausanne). 2024; 15:1461642.

PMID: 39355618 PMC: 11442314. DOI: 10.3389/fendo.2024.1461642.

The effect of circulating cytokines on the risk of systemic lupus erythematosus: Mendelian randomization and observational study.

Xue D, Qian Y, Tu X, He M, Xing F, Ren Y Immunogenetics. 2024; 76(5-6):315-322.

PMID: 39183206 PMC: 11496328. DOI: 10.1007/s00251-024-01351-x.

Siglec-1, an easy and contributory inflammation marker in rheumatology.

Boz V, Tesser A, Burlo F, Donadel N, Pastore S, Amaddeo A Clin Transl Immunology. 2024; 13(7):e1520.

PMID: 38939726 PMC: 11208081. DOI: 10.1002/cti2.1520.

Noninvasive biomarkers for lupus nephritis.

Liu T, Yang Y, Zhou Y, Jiang Y Lab Med. 2024; 55(5):535-542.

PMID: 38493322 PMC: 11371907. DOI: 10.1093/labmed/lmae015.

Anti-histone and anti-nucleosome rather than anti-dsDNA antibodies associate with IFN-induced biomarkers in Sudanese and Swedish SLE patients.

Elbagir S, Mohammed N, Oke V, Larsson A, Nilsson J, Elshafie A Rheumatology (Oxford). 2024; 64(3):1170-1178.

PMID: 38460182 PMC: 11879337. DOI: 10.1093/rheumatology/keae134.

References

Noris M, Bernasconi S, Casiraghi F, Sozzani S, Gotti E, Remuzzi G . Monocyte chemoattractant protein-1 is excreted in excessive amounts in the urine of patients with lupus nephritis. Lab Invest. 1995; 73(6):804-9. View

Rovin B, Song H, Birmingham D, Hebert L, Yu C, Nagaraja H . Urine chemokines as biomarkers of human systemic lupus erythematosus activity. J Am Soc Nephrol. 2004; 16(2):467-73. DOI: 10.1681/ASN.2004080658. View

Wada T, Yokoyama H, Tomosugi N, Hisada Y, Ohta S, Naito T . Detection of urinary interleukin-8 in glomerular diseases. Kidney Int. 1994; 46(2):455-60. DOI: 10.1038/ki.1994.293. View

Bombardier C, Gladman D, Urowitz M, Caron D, Chang C . Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992; 35(6):630-40. DOI: 10.1002/art.1780350606. View

Wolf R, Brelsford W . Soluble interleukin-2 receptors in systemic lupus erythematosus. Arthritis Rheum. 1988; 31(6):729-35. DOI: 10.1002/art.1780310605. View

Hooks J, Moutsopoulos H, Geis S, Stahl N, Decker J, Notkins A . Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med. 1979; 301(1):5-8. DOI: 10.1056/NEJM197907053010102. View

Petri M . Hopkins Lupus Cohort. 1999 update. Rheum Dis Clin North Am. 2000; 26(2):199-213, v. DOI: 10.1016/s0889-857x(05)70135-6. View

Lit L, Wong C, Tam L, Li E, Lam C . Raised plasma concentration and ex vivo production of inflammatory chemokines in patients with systemic lupus erythematosus. Ann Rheum Dis. 2005; 65(2):209-15. PMC: 1798029. DOI: 10.1136/ard.2005.038315. View

Zlotnik A, Yoshie O . Chemokines: a new classification system and their role in immunity. Immunity. 2000; 12(2):121-7. DOI: 10.1016/s1074-7613(00)80165-x. View

10.

Graham R, Kozyrev S, Baechler E, Reddy M, Plenge R, Bauer J . A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat Genet. 2006; 38(5):550-5. DOI: 10.1038/ng1782. View

11.

Shi K, Hayashida K, Kaneko M, Hashimoto J, Tomita T, Lipsky P . Lymphoid chemokine B cell-attracting chemokine-1 (CXCL13) is expressed in germinal center of ectopic lymphoid follicles within the synovium of chronic arthritis patients. J Immunol. 2000; 166(1):650-5. DOI: 10.4049/jimmunol.166.1.650. View

12.

Hoffman R . T cells in the pathogenesis of systemic lupus erythematosus. Clin Immunol. 2004; 113(1):4-13. DOI: 10.1016/j.clim.2004.05.001. View

13.

Holcombe R, Baethge B, Wolf R, Betzing K, Stewart R, HALL V . Correlation of serum interleukin-8 and cell surface lysosome-associated membrane protein expression with clinical disease activity in systemic lupus erythematosus. Lupus. 1994; 3(2):97-102. DOI: 10.1177/096120339400300207. View

14.

Jacobi A, Odendahl M, Reiter K, Bruns A, Burmester G, Radbruch A . Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum. 2003; 48(5):1332-42. DOI: 10.1002/art.10949. View

15.

Wong C, Li E, Ho C, Lam C . Elevation of plasma interleukin-18 concentration is correlated with disease activity in systemic lupus erythematosus. Rheumatology (Oxford). 2000; 39(10):1078-81. DOI: 10.1093/rheumatology/39.10.1078. View

16.

Lee I, Wang L, Wells A, Dorf M, Ozkaynak E, Hancock W . Recruitment of Foxp3+ T regulatory cells mediating allograft tolerance depends on the CCR4 chemokine receptor. J Exp Med. 2005; 201(7):1037-44. PMC: 2213137. DOI: 10.1084/jem.20041709. View

17.

Meller S, Winterberg F, Gilliet M, Muller A, Lauceviciute I, Rieker J . Ultraviolet radiation-induced injury, chemokines, and leukocyte recruitment: An amplification cycle triggering cutaneous lupus erythematosus. Arthritis Rheum. 2005; 52(5):1504-16. DOI: 10.1002/art.21034. View

18.

Narumi S, Takeuchi T, Kobayashi Y, Konishi K . Serum levels of ifn-inducible PROTEIN-10 relating to the activity of systemic lupus erythematosus. Cytokine. 2000; 12(10):1561-5. DOI: 10.1006/cyto.2000.0757. View

19.

Grewal I, RUTLEDGE B, Fiorillo J, Gu L, Gladue R, Flavell R . Transgenic monocyte chemoattractant protein-1 (MCP-1) in pancreatic islets produces monocyte-rich insulitis without diabetes: abrogation by a second transgene expressing systemic MCP-1. J Immunol. 1997; 159(1):401-8. View

20.

Baechler E, Batliwalla F, Karypis G, Gaffney P, Ortmann W, Espe K . Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A. 2003; 100(5):2610-5. PMC: 151388. DOI: 10.1073/pnas.0337679100. View